A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

Trial Profile

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

Completed
Phase of Trial: Phase II/III

Latest Information Update: 23 May 2017

At a glance

  • Drugs AC 1204 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms NOURISH-AD
  • Sponsors Accera
  • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jun 2017.
    • 28 Feb 2017 According to Accera Media Release, results of phase 3 study will be presented at the Alzheimer's Association International Conference in London in July 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top